BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC).

波士顿，2024年5月2日（环球通讯社）--全球全方位服务临床合同研究组织（CRO）Novotech与生物技术公司合作，在每个阶段加速开发先进和新颖的治疗方法，已任命ScottSchliebner为副总裁兼药物开发咨询（DDC）全球负责人。

Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive 'inception to approval' services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company.

Novotech首席医疗官Judith Ng Cashin博士表示：“我们欢迎Scott加入医疗和科学团队。他是一位久经考验的战略性，创新性和以商业为中心的生命科学高管，在生物制药和CRO领域拥有约30年的经验。他为我们的世界级DDC团队带来了宝贵的领导力，DDC团队是一个全方位服务的全球药物开发和战略监管团队，提供全面的“从开始到批准”服务。”DDC与biotechs合作，优化适合目的的治疗开发策略，既推进了开发计划，又为公司创造了价值。

To do this, DDC leverages CMC/manufacturing, toxicology, clinical/medical and regulatory affairs experts with extensive industry experience covering all phases ​of drug development. It also offers a fully integrated regulatory affairs team with an experienced, speed orientated mindset to increase the probability of regulatory and commercial success.​ The DDC team has experience in a comprehensive range of indications for drugs, novel antibodies, recombinant protein therapeutics, small molecules, vaccines, cell therapy, devices, and combination products, throughout all phases of program development (Phases I - IV) and commercialization.

为此，DDC利用CMC/制造、毒理学、临床/医学和监管事务专家，这些专家拥有涵盖所有阶段的丰富行业经验​药物开发。它还提供了一个全面整合的监管事务团队，具有经验丰富、以速度为导向的思维方式，以提高监管和商业成功的可能性。​ DDC团队在药物，新型抗体，重组蛋白治疗剂，小分子，疫苗，细胞治疗，设备和组合产品的所有适应症方面都有丰富的经验，贯穿于项目开发的所有阶段（阶段I-IV）和商业化。

Scott Schliebner said he was extremely pleased to join the DDC team. “I bring a strategic and consultative approach to building and growing life sciences businesses, with a focus on developi.

斯科特·施利布纳（ScottSchliebner）表示，他非常高兴加入DDC团队。“我提出了一种战略和咨询方法来建立和发展生命科学业务，重点是发展。